1) teniposide
替尼泊苷
1.
Determination of teniposide in rat plasma by HPLC-UV;
HPLC法测定大鼠血浆中替尼泊苷浓度
2.
Allergic shock following injection of teniposide;
替尼泊苷注射液引起过敏性休克
3.
Teniposide inducing apoptosis and G2/M phase arrest of Tca8113 cells;
替尼泊苷诱导Tca8113细胞凋亡及细胞周期阻滞的实验观察
2) VM-26
替尼泊苷
1.
Effects of 5-FU and VM-26 on proliferation and apoptosis of gastric cancer cell line BGC-823
5-氟尿嘧啶联合替尼泊苷对胃癌BGC-823细胞增殖和凋亡的影响
2.
Aim:To assess the effect of low-dose VM-26 combined with thalidomide on growth and neoplastic angiogenesis of transplanted human gastric adenocarcinoma BGC-823 tumor and the change of the bone marrow hematopoietic function in nude mice.
目的:探讨低剂量替尼泊苷(VM-26)联合沙利度胺对人胃癌BGC-823细胞裸鼠移植瘤生长、荷瘤小鼠骨髓造血功能的变化及新生血管形成的影响。
3.
Aim:For the better treatment of advanced gastric cancer,the chemotherapy regimens of VCF (VM-26+CDDP+5-FU) and ECF (VP-16 +CDDP+5-FU) were used to explore their clinical therapeutic effect and application prospects.
目的:观察顺铂(CDDP)和5-氟尿嘧啶(5-FU)联合替尼泊苷(VM-26)组成的VCF方案或联合依托泊甙(VP-16)组成的ECF方案治疗胃癌的疗效。
3) Teniposide
替尼泊甙
1.
Effects of Teniposide on Cell Cycle Phase and Apoptosis of Gastric Carcinoma Cell Lines;
替尼泊甙对胃癌细胞凋亡及细胞周期的影响
2.
Clinical effect of temozolomide vs teniposide and lomustine in patients with malignant glioma;
单用替莫唑胺与替尼泊甙联合洛莫司汀治疗恶性胶质瘤的比较
3.
Effects of teniposide combined with other anticancer drugs on proliferation of BGC-823 cell lines in vitro;
替尼泊甙联合其他抗肿瘤药对BGC-823细胞体外增殖的影响
4) VM-26
替尼泊甙
1.
The influences of Actinomycin D and VM-26 on proliferation in rat glioma cell line C_6;
放线菌素D和替尼泊甙对大鼠胶质瘤细胞增殖影响的实验研究
2.
Objective To study the therapeutic effect of actimomycin D (ACTD) and VM-26 on rat C6 glioma invivo.
目的研究放线菌素D(ACTD)、替尼泊甙(VM-26)对大鼠胶质瘤细胞增殖的体内治疗效果。
3.
Objective To investigate the curative effect of intravenous chemotherapy with BVD(BCNU+VM-26+DDP) in treating brain gliomas after surgical excision.
目的探讨脑胶质瘤术后应用BVD方案(卡氮芥+替尼泊甙+顺铂)静脉化疗的临床疗效。
5) tineposide
替尼泊甙
1.
Enhancement of cisplatin on cytocidal effect of tineposide against small cell lung cancer cell line;
顺铂增强替尼泊甙杀伤小细胞肺癌细胞系的作用
2.
Objective: To investigate the expressions of topoisomeraseII and transcription factor Sp1 (Specificity protein-1) in theprocess of cisplatin influencing on tineposide killing the smallcell lung cancer cells.
目的:探讨DNA拓扑异构酶II (topoisomerase II, Topo II)及特化蛋白1(Specificity protein-1, Sp1)在顺铂(cisplatin,CDDP)对替尼泊甙(tineposide, VM-26)杀伤小细胞肺癌(small cell lung cancer, SCLC)细胞影响过程中的表达。
6) irisolidon
尼泊尔鸢尾苷元
1.
Water-soluble irisolidon sulfonate(5,7-hydroxyl-4′,6-dimethoxyl-isoflavone-3′-sulfonate) was synthesized by sulfonation and it was characterized by IR,NMR spectrum and elemental analysis.
以尼泊尔鸢尾苷元(5,7-二羟基-4,′6-二甲氧基异黄酮)为原料通过磺化反应合成了水溶性化合物尼泊尔鸢尾异黄酮-3′-磺酸钠(5,7-二羟基-4,′6-二甲氧基异黄酮-3′-磺酸钠),并采用IR,NMR及元素分析法对其结构进行表征。
补充资料：替尼泊苷
分子式：
CAS号：
性质：又名威猛。本品为中性亲脂性物质，几乎不溶于水，溶于有机溶剂。以从植物中提取的鬼臼毒素为原料，经缩合、还原、缩合而制得本品，为表鬼臼毒的半合成衍生物。为抗肿瘤药，作用为VP-16的5～10倍，与VP-16有交叉耐药。临床主要用于小细胞肺癌，急性淋巴白血病、神经母细胞瘤和淋巴瘤。
CAS号：
性质：又名威猛。本品为中性亲脂性物质，几乎不溶于水，溶于有机溶剂。以从植物中提取的鬼臼毒素为原料，经缩合、还原、缩合而制得本品，为表鬼臼毒的半合成衍生物。为抗肿瘤药，作用为VP-16的5～10倍，与VP-16有交叉耐药。临床主要用于小细胞肺癌，急性淋巴白血病、神经母细胞瘤和淋巴瘤。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条